Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Fate Therapeutics, Inc. FATE

Set alert

Price alert · FATE

All alert types
2.06 USD +0.05 +2.49%

As of Nov 3, 1:37 PM ET

Bid
2.05 × 2
Ask
2.06 × 2
2.02 Day range 2.12
0.95 52-week range 3.23
YTD
+110.20%
1 year
+63.49%
Open
2.02
Prev close
2.01
Mkt cap
246.83M
Vol
371.13K
Avg vol
1.58M
EPS
-1.05
P/E
0.00
Div yield
0.00%
More statistics
Low
2.02
High
2.12
Forward P/E
-0.99
Beta
1.88
Short ratio
3.10
Inst. own
102.25%
Dividend
0.00
Ex-div date
50-d avg
2.53
200-d avg
3.93
1y target
6.31

3M chart

Chart tools
Interval
1m5m15m30m

Signals (13)
NameDateAgo
MACD: Buy SignalOct 22, 20261 week ago
RSI: OversoldOct 14, 20262 weeks ago
MACD: Sell SignalSep 25, 20261 month ago
SMA: BearishSep 23, 20261 month ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BullishSep 17, 20261 month ago
MACD: Buy SignalSep 17, 20261 month ago
SMA: BearishAug 20, 20262 months ago
MACD: Sell SignalAug 14, 20262 months ago
SMA: BearishAug 12, 20262 months ago
MACD: Buy SignalAug 10, 20262 months ago
SMA: BullishAug 7, 20262 months ago

Analyst view

Consensus: buy

Buy
Price target (mean) 6.31 +206.2% upside
Target (low)
3.00
Target (mean)
6.31
Target (high)
10.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
  • Strong buy2
  • Buy4
  • Hold12
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 18
  • 1 month ago 18
  • 2 months ago 17

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

FATE analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.43055-0.49 – -0.35-0.45+4.3%1.57M-6.5%14
Next quarter-0.455-0.50 – -0.38-0.47+3.2%1.20M-37.8%8
Current year-1.59-1.77 – -1.18-1.64+3.2%13.65M-78.5%14
Next year-1.63-2.07 – -0.80-1.59-2.9%4.19M-69.3%14

Upgrades and downgrades

The latest rating changes

FATE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2024NeedhamReiterated—Hold
Nov 13, 2024NeedhamReiterated—Hold
Aug 22, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Aug 14, 2024NeedhamReiterated—Hold
Jun 17, 2024Piper SandlerUpgradeNeutralOverweight
May 16, 2024HC Wainwright & Co.MaintainedNeutralNeutral
May 10, 2024Canaccord GenuityMaintainedBuyBuy
May 10, 2024BMO CapitalMaintainedMarket PerformMarket Perform
May 10, 2024WedbushMaintainedNeutralNeutral
May 10, 2024Piper SandlerMaintainedNeutralNeutral
May 6, 2024WedbushReiteratedNeutralNeutral
Apr 23, 2024WedbushReiteratedNeutralNeutral
Apr 11, 2024NeedhamReiterated—Hold
Mar 28, 2024B of A SecuritiesMaintainedUnderperformUnderperform
Mar 19, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Feb 27, 2024Morgan StanleyMaintainedEqual-WeightEqual-Weight
Feb 27, 2024BMO CapitalMaintainedMarket PerformMarket Perform
Feb 27, 2024BarclaysMaintainedOverweightOverweight
Feb 27, 2024WedbushMaintainedNeutralNeutral
Feb 27, 2024OppenheimerReiteratedPerformPerform
Nov 20, 2023MizuhoMaintainedBuyBuy
Nov 13, 2023Morgan StanleyMaintainedEqual-WeightEqual-Weight
Nov 9, 2023BMO CapitalMaintainedMarket PerformMarket Perform
Nov 9, 2023WedbushMaintainedNeutralNeutral
Nov 9, 2023Wells FargoMaintainedEqual-WeightEqual-Weight
Sep 7, 2023Cantor FitzgeraldReiteratedNeutralNeutral
Aug 16, 2023Truist SecuritiesReiteratedHoldHold
Aug 10, 2023Morgan StanleyMaintainedEqual-WeightEqual-Weight
Aug 10, 2023BarclaysMaintainedOverweightOverweight
Aug 9, 2023BMO CapitalMaintainedMarket PerformMarket Perform